Aggressive fibromatosis - surgical approach as a part of combined treatment

Cover Page

Cite item

Full Text

Abstract

Aim of the study. To evaluate results of surgery alone in the treatment of aggressive fibromatosis during past 4 years. Materials and methods. From January 2006 till January 2010 in the dept, of orthopedic surgery 32 patients with extra abdominal aggressive fibromatosis underwent 38 surgeries (6 patients received additional surgeries due to local relapses). 9 male (28%) and 23 (72%) female patients were included in the trial. Median age was 31 year (16-70 y.o.). 12 patients (37,5%) out of 32 were with primary tumor, 18 (56%) with relapse tumors and 2 (6,5%) patients with undefinitive surgery made elsewhere. 12 (37%) patients out 32 underwent preplanned bone resections and 11 reconstructive surgery was done. Results. In 12 (31%) pathology reported positive margins (Rl) and the wrest were R0. 11 patients had disease progression 3 to 18 month after the surgery, 4 patients were lost of follow up. 7 patients are undergoing conservative treatment for tumor recurrence. 21 (66%) patient is alive without progression with follow up from 3 to 49 month (median follow up 17 months). Following negative prognostic factors were observed: multifocal tumor growth, tumor volume more then 1000 cm3, tumor location near the joints, in soft tissues of forearm, arm, hand, lower leg and foot. Conclusion. Negative margins does not guarantee that tumor will not relapse even with addition of RT or/and chemotherapy and in opposite, sometimes in patients with positive margins recurrence is not observed.

About the authors

S. L. Daryalova

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Author for correspondence.
Russian Federation

G. A. Frank

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

V. U. Karpenko

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

A. L. Ilushin

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

A. V. Bukharov

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

V. A. Derzhavin

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

S. V. Epifanova

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

O. V. Novikova

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Russian Federation

V. V. Teplyakov

P.A. Herzen Moscow Research Oncological Institute Rosmedtechnology

Email: oncolog59@yandex.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2010 Daryalova S.L., Frank G.A., Karpenko V.U., Ilushin A.L., Bukharov A.V., Derzhavin V.A., Epifanova S.V., Novikova O.V., Teplyakov V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.